697 related articles for article (PubMed ID: 33106987)
1. Role of Oxidative Stress on SARS-CoV (SARS) and SARS-CoV-2 (COVID-19) Infection: A Review.
Suhail S; Zajac J; Fossum C; Lowater H; McCracken C; Severson N; Laatsch B; Narkiewicz-Jodko A; Johnson B; Liebau J; Bhattacharyya S; Hati S
Protein J; 2020 Dec; 39(6):644-656. PubMed ID: 33106987
[TBL] [Abstract][Full Text] [Related]
2. Shedding Light on the Inhibitory Mechanisms of SARS-CoV-1/CoV-2 Spike Proteins by ACE2-Designed Peptides.
Freitas FC; Ferreira PHB; Favaro DC; Oliveira RJ
J Chem Inf Model; 2021 Mar; 61(3):1226-1243. PubMed ID: 33619962
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of ACE2-Spike Interaction by an ACE2 Binder Suppresses SARS-CoV-2 Entry.
Shin YH; Jeong K; Lee J; Lee HJ; Yim J; Kim J; Kim S; Park SB
Angew Chem Int Ed Engl; 2022 Mar; 61(11):e202115695. PubMed ID: 35043545
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of S-protein RBD and hACE2 Interaction for Control of SARSCoV- 2 Infection (COVID-19).
Nayak SK
Mini Rev Med Chem; 2021; 21(6):689-703. PubMed ID: 33208074
[TBL] [Abstract][Full Text] [Related]
5. Potential therapeutic approaches for the early entry of SARS-CoV-2 by interrupting the interaction between the spike protein on SARS-CoV-2 and angiotensin-converting enzyme 2 (ACE2).
Xiang Y; Wang M; Chen H; Chen L
Biochem Pharmacol; 2021 Oct; 192():114724. PubMed ID: 34371003
[TBL] [Abstract][Full Text] [Related]
6. Epigallocatechin gallate (EGCG) attenuates severe acute respiratory coronavirus disease 2 (SARS-CoV-2) infection by blocking the interaction of SARS-CoV-2 spike protein receptor-binding domain to human angiotensin-converting enzyme 2.
Ohishi T; Hishiki T; Baig MS; Rajpoot S; Saqib U; Takasaki T; Hara Y
PLoS One; 2022; 17(7):e0271112. PubMed ID: 35830431
[TBL] [Abstract][Full Text] [Related]
7. Aptamer Blocking Strategy Inhibits SARS-CoV-2 Virus Infection.
Sun M; Liu S; Wei X; Wan S; Huang M; Song T; Lu Y; Weng X; Lin Z; Chen H; Song Y; Yang C
Angew Chem Int Ed Engl; 2021 Apr; 60(18):10266-10272. PubMed ID: 33561300
[TBL] [Abstract][Full Text] [Related]
8. Dynamics of the ACE2-SARS-CoV-2/SARS-CoV spike protein interface reveal unique mechanisms.
Ali A; Vijayan R
Sci Rep; 2020 Aug; 10(1):14214. PubMed ID: 32848162
[TBL] [Abstract][Full Text] [Related]
9. Flavonols as potential antiviral drugs targeting SARS-CoV-2 proteases (3CL
Mouffouk C; Mouffouk S; Mouffouk S; Hambaba L; Haba H
Eur J Pharmacol; 2021 Jan; 891():173759. PubMed ID: 33249077
[TBL] [Abstract][Full Text] [Related]
10. The Two-Way Switch Role of ACE2 in the Treatment of Novel Coronavirus Pneumonia and Underlying Comorbidities.
Pang XC; Zhang HX; Zhang Z; Rinkiko S; Cui YM; Zhu YZ
Molecules; 2020 Dec; 26(1):. PubMed ID: 33396184
[TBL] [Abstract][Full Text] [Related]
11. Receptor utilization of angiotensin-converting enzyme 2 (ACE2) indicates a narrower host range of SARS-CoV-2 than that of SARS-CoV.
Wang Q; Qiu Y; Li JY; Liao CH; Zhou ZJ; Ge XY
Transbound Emerg Dis; 2021 May; 68(3):1046-1053. PubMed ID: 32794346
[TBL] [Abstract][Full Text] [Related]
12. Repositioning of histamine H
Ge S; Wang X; Hou Y; Lv Y; Wang C; He H
Eur J Pharmacol; 2021 Apr; 896():173897. PubMed ID: 33497607
[TBL] [Abstract][Full Text] [Related]
13. Nonmuscle myosin heavy chain IIA facilitates SARS-CoV-2 infection in human pulmonary cells.
Chen J; Fan J; Chen Z; Zhang M; Peng H; Liu J; Ding L; Liu M; Zhao C; Zhao P; Zhang S; Zhang X; Xu J
Proc Natl Acad Sci U S A; 2021 Dec; 118(50):. PubMed ID: 34873039
[TBL] [Abstract][Full Text] [Related]
14. Severe acute respiratory syndrome coronavirus entry as a target of antiviral therapies.
Kuhn JH; Li W; Radoshitzky SR; Choe H; Farzan M
Antivir Ther; 2007; 12(4 Pt B):639-50. PubMed ID: 17944271
[TBL] [Abstract][Full Text] [Related]
15. The Combination of Bromelain and Acetylcysteine (BromAc) Synergistically Inactivates SARS-CoV-2.
Akhter J; Quéromès G; Pillai K; Kepenekian V; Badar S; Mekkawy AH; Frobert E; Valle SJ; Morris DL
Viruses; 2021 Mar; 13(3):. PubMed ID: 33800932
[TBL] [Abstract][Full Text] [Related]
16. Identification of SARS-CoV-2 Receptor Binding Inhibitors by In Vitro Screening of Drug Libraries.
David AB; Diamant E; Dor E; Barnea A; Natan N; Levin L; Chapman S; Mimran LC; Epstein E; Zichel R; Torgeman A
Molecules; 2021 May; 26(11):. PubMed ID: 34072087
[TBL] [Abstract][Full Text] [Related]
17. Can Host Cell Proteins Like ACE2, ADAM17, TMPRSS2, Androgen Receptor be the Efficient Targets in SARS-CoV-2 Infection?
Gupta VK; Murthy MK; Patil S
Curr Drug Targets; 2021; 22(10):1149-1157. PubMed ID: 33243116
[TBL] [Abstract][Full Text] [Related]
18. Binding and entering: COVID finds a new home.
Vu MN; Menachery VD
PLoS Pathog; 2021 Aug; 17(8):e1009857. PubMed ID: 34460863
[TBL] [Abstract][Full Text] [Related]
19. Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity.
Zhu Y; Yu D; Yan H; Chong H; He Y
J Virol; 2020 Jul; 94(14):. PubMed ID: 32376627
[TBL] [Abstract][Full Text] [Related]
20. The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19.
Li K; Meyerholz DK; Bartlett JA; McCray PB
mBio; 2021 Aug; 12(4):e0097021. PubMed ID: 34340553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
